PreludeDx™ Presents New DCISionRT® Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting

DCISionRT with Novel Residual Risk Subtype Identifies Patients Who May Not Benefit from ET after Surgery and Radiation LAGUNA HILLS, Calif., June 7, 2022 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast…